Here, we investigated this synthetic lethal interaction in SMARCA4-deficient NSCLC, which has a complex mutation landscape, and explored the potential strategy of using CDK4/6 inhibitors to treat this highly aggressive subgroup of lung cancer. This evidence concerns the gene CDK4 and lung carcinoma.